No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
ApicHope Pharmaceutical Co., Ltd, along with its various subsidiary entities, operates primarily in the pharmaceutical sector, focusing on the research, development, production, and distribution of medicinal products. The company boasts an extensive portfolio of offerings that address diverse therapeutic needs, including solutions for infectious diseases, pediatric health, cardiovascular conditions, genitourinary disorders, respiratory ailments, liver and digestive problems, and dermatological complaints. Furthermore, they supply a range of anti-inflammatory and pain-relieving medications. This enterprise, established in 2002, maintains its primary operations in Guangzhou, China. It adopted its current name, ApicHope Pharmaceutical Co., Ltd, in December 2021, having previously been known as Yipinhong Pharmaceutical Co.,Ltd.
www.apichope.comNo one on the platform currently holds 300723.SZ.
No tracked institution reports a position in 300723.SZ as of their last filing.
No one on the platform has traded 300723.SZ yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | -35.7% | -11.1% | ||||
| Profit Margin % | -36.2% | -7.9% | 2.0% | |||
| Free Cash Flow Margin % | -8.7% | -15.0% | -5.0% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $1.1B | -34.5% | $1.16 | $1.16–$1.16 | — | 1 |
| 2027 | $1.3B | +16.5% | $-0.23 | $-0.23–$-0.23 | — | 1 |
| 2028 | $1.5B | +17.5% | $-0.32 | $-0.32–$-0.32 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 0 of the last 2 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2025-04-24 | $0.15 | $0.13 | -15.5% |
| 2025-04-24 | $0.15 | $-0.65 | -533.3% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 300723.SZApicHope Pharmaceutical Co., Ltd | $33.45 | +0.36% | $15.1B | — |
| 000623.SZJilin Aodong Pharmaceutical Group Co., Ltd. | $17.37 | -0.17% | $20.8B | — |
| 000766.SZTonghua Golden-Horse Pharmaceutical Industry Co,Ltd | $15.40 | -1.66% | $14.9B | — |
| 002262.SZJiangsu Nhwa Pharmaceutical Co., Ltd. | $21.65 | -0.64% | $22.0B | — |
| 300558.SZBetta Pharmaceuticals Co., Ltd. |
| $45.97 |
| -0.52% |
| $19.5B |
| — |
| 600062.SSChina Resources Double-Crane Pharmaceutical Co.,Ltd. | $15.94 | -0.25% | $16.6B | — |
| 600329.SSTianjin Pharmaceutical Da Ren Tang Group Corporation Limited | $34.00 | -0.23% | $19.4B | — |
Source: Financial Modeling Prep · peers by sector/industry